Get the Stockscreener App
16.32
4.48%
0.70
Zenas Biopharma Inc stock is traded at $16.32, with a volume of 222.56K.
It is up +4.48% in the last 24 hours and up +62.87% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$15.62
Open:
$15.69
24h Volume:
222.56K
Relative Volume:
1.29
Market Cap:
$682.73M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+23.82%
1M Performance:
+62.87%
6M Performance:
+111.13%
1Y Performance:
+0.00%
1-Day Range:
$15.44
$16.67
1-Week Range:
$13.07
$16.67
52-Week Range:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.32 | 598.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
What analysts say about Zenas BioPharma Inc. stockRecord-setting profit potential - jammulinksnews.com
Zenas BioPharma Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com
Is Zenas BioPharma Inc. a good long term investmentFree Consultation - jammulinksnews.com
What drives Zenas BioPharma Inc. stock priceStrong return on assets - jammulinksnews.com
IgG4-Related Disease Market Outlook Driven by Advancing - openPR.com
What makes Zenas BioPharma Inc. stock price move sharplyFree Stock Market Group - beatles.ru
Why Zenas BioPharma Inc. stock attracts strong analyst attentionHigh Return Investment Tips - Newser
How Zenas BioPharma Inc. stock performs during market volatilityFree Stock Tips Group - Newser
Zenas BioPharma Insiders Added US$2.11m Of Stock To Their Holdings - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Stockholders to Reach Out - ACCESS Newswire
Citi reiterates Buy rating on Zenas Biopharma stock with $27 price target - Investing.com Canada
ZBIO Crosses Above Key Moving Average Level - Nasdaq
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments - TipRanks
Morgan Stanley assumes coverage on Zenas Biopharma stock with Overweight rating - Investing.com Canada
Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma - TipRanks
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 2000 Growth Index - MarketScreener
Rhumbline Advisers Sells 27,428 Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) - Defense World
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesZBIO - Finansavisen
ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas - GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Business Wire
Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO)Levi & Korsinsky Reminds Investors of June 16, 2025 - ACCESS Newswire
ZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - marketscreener.com
FINAL ALERT NOTICEZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsZBIO - marketscreener.com
June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - The Malaysian Reserve
Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO)Contact Levi & Korsinsky Before June 16, 2025 - ACCESS Newswire
Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class ActionContact Levi & Korsinsky - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - StreetInsider
Zenas BioPharma, Inc. Sued for Securities Law Violations – - GlobeNewswire
ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm - GuruFocus
Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & ... - Bluefield Daily Telegraph
ZBIO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW - GlobeNewswire
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):